#### ROMICAT II - Rule Out Myocardial Ischemia/Infarction Using Computer Assisted Tomography

#### NHLBI U01HL092040

A Multicenter Randomized Comparative Effectiveness Trial of Cardiac CTA vs. Standard Evaluation in Acute Chest Pain Patients in the Emergency Department

Udo Hoffmann, Quynh A. Truong, Hang Lee, Eric Chou, Pamela K. Woodard, John T. Nagurney, James H. Pope, Thomas Hauser, Charles White, Scott Weiner, Alexander Goehler, Pearl Zakroysky, Ruth Kirby, Douglas Hayden, Stephen D. Wiviott, Jerome Fleg, G. Scott Gazelle, David Schoenfeld, James E. Udelson for the ROMICAT II Investigators







U.H.: Research/Research Grants: NIH; Siemens Medical Systems Q.A.T.: Research/Research Grants: Qi Imaging; St. Jude Medical; NIH T.H.: Consulting Fees/Honoraria: Astellas, Harvard Cardiovascular Research Institute. P.K.W.: Consulting Fees/Honoraria: Medtronic; Research/Research Grants: Astellas, Lantheus, Siemens Medical Systems; Speaker's Bureau Lantheus J.E.U.: Research/Research Grants: NIH J.T.N.: Research/Research Grants: Alere-Biosite, Brahms-Thermo Fisher Scientific, Nanosphere, Clindevor All other authors: None

#### Background



- Chest pain (CP) suggestive of ACS most common presentation to the ED
- Current strategies to rule out ACS are inefficient – overcrowded ED's, unnecessary admissions
- Despite a low threshold to admit patients up to 2% of pts discharged from EDs with missed ACS

## Cardiac CT Angiography (CCTA) ROMICAT II

- Accurate noninvasive detection of significant CAD, especially high NPV
- ROMICAT I blinded observational study of CCTA in acute CP/low-int risk of ACS:
  - Low prevalence of ACS (8%)
  - CCTA most pts have no CAD or nonobstructive plaque
  - CCTA very high NPV to R/O ACS

## Equipoise




 CCTA may enable earlier but safe triage, reducing hospital admissions and length of stay as compared to standard ED evaluation

 Medicare data suggest a doubling in procedures and costs after CCTA compared to functional testing



In a randomized controlled multicenter trial, a CCTA based evaluation strategy will improve the effectiveness of clinical decision making as compared to a standard ED evaluation in pts with acute chest pain suggestive of ACS.

## Study Design



**ROMICAT II** 



 >5 minutes of CP or equivalent within 24 hours prior to ED presentation, warranting further risk stratification

- 40 to 74 years of age
- Able to hold breath for at least 10 seconds
- Sinus rhythm

#### **Exclusion Criteria**

## **ROMICAT II**

- New diagnostic ischemic ECG changes
- Documented or self-reported history of CAD
- >6 hours since presentation to ED to time of consent
- Body mass index >40 kg/m2
- Impaired renal function
- Troponin elevation consistent with MI
- Acute cocaine use within the past 48 hours
- Hemodynamic or clinical instability
- CT contraindications allergy, asthma, metformin therapy, positive pregnancy test, contraindication to beta blockers



**ROMICAT II** 


Length of Hospital Stay (LOS)	Primary Endpoint
Rates of Missed ACS within 72 hours after ED Discharge MACE <sup>*</sup> within at 28 days Peri-procedural Complications	Secondary Endpoints Safety
Rates of Direct ED Discharge Time to Diagnosis Resource Utilization Costs of Care	Secondary Endpoints Effectiveness
Cumulative Radiation Exposure during Index Hospitalization and Follow-up	Tertiary Endpoints
* death MI LIAD urrent reveasulari	

<sup>f</sup> death, MI, UAP, urgent revascularization



 1000 patients to detect a difference ≥8.3 hours in mean LOS with 86% power by a two-sided t-test at p< 0.05 - based on projections from ROMICAT I

# Flow of Patients Through the Trial ROMICAT II



\*Last patient randomized January 31<sup>st</sup> 2012; \*\* Last patient follow-up March 16<sup>th</sup> 2012

#### **Patient Characteristics**



	CCTA (N=501)	Standard ED Eval (N=499)	p-value
Demographics			
Age (years, mean $\pm$ SD)	54±8	54±8	0.49
Female Gender (%)	47.7	45.9	0.57
Caucasian (%)	65.9	66.1	0.95
Non-Hispanic (%)	86.8	84.6	0.57
Major Cardiovascular Risk Factors			
0-1 / 2-3 / ≥4 risk factors (%)	36/54/10	39/51/10	0.68
Chief Complaint at ED Presentation (n,%)			0.47
Anginal chest pain or equivalent Arm/Jaw/Shoulder/Epigastric Pain Shortness of Breath Other	444 (88.6) 21 (4.2) 7 (1.4) 29 (5.8)	451 (90.6) 16 (3.2) 10 (2.0) 21 (4.2)	
Discharge Diagnosis Index ED Visit or Hospitalization			
ACS n (%)* Unstable angina pectoris (n, %) Myocardial infarction (n, %)	43 (8.6) 35 (7.0) 8 (1.6)	32 (6.4) 17 (3.4) 15 (3.0)	0.23 0.01 0.01


\*Agreement between site and independent adjudication for discharge diagnosis was excellent (96.5 %; kappa: 0.9)

Primary Endpoint - Length of Hospital Stay

Mean LOS <u>+</u> SD (hrs)	ССТА	Standard ED Eval	p-value
All	23.2 ± 37.0	30.8 ± 28.0	0.0002
Final Dx not ACS	17.2 ±24.6	27.2 ± 19.5	<0.0001
Final Dx ACS	86.3 ±72.2	83.8 ±61.3	0.87

ROMICAT II

#### Primary Outcome - Length of Hospital Stay



**ROMICAT II** 

### Secondary Endpoints - Safety



	ССТА N=501	Standard ED Eval N=499	p-value
<b>Safety</b> Missed ACS (n, %) Peri-procedural Complications (n, %)	0 (0) 2 (0.4)	0 (0) 0 (0)	- 0.25
Follow-up at 28 days MACE (n, %)	2 (0.4)	5 (1.0)	0.37

#### **Peri-procedural Complications**

• Peri-operative bleeding after re-implantation of an anomalous coronary artery

• Increase in creatinine after renal stone and hydronephrosis

# Secondary Effectiveness Endpoints ROMICATII

	ССТА	Standard ED Eval	p-value
Patient Disposition (n, %)			0.001
Direct ED Discharge	234 (46.7%)	62 (12.4%)	
Admission to Obs Unit	133 (26.6%)	268 (53.7%)	
Admission to Hospital	127 (25.4%)	158 (31.7%)	
Left AMA	7 (1.3%)	11 (2.2%)	
Time to Diagnosis in hours (mean ± SD)	10.4 ± 12.6	18.7 ± 11.8	0.0001
Follow-up for recurrent			
CP by 28 days (n)			
Repeat ED Visits	13	19	0.29
Repeat Hospitalizations	7	7	-

#### Testing, Interventions, and Radiation

	ССТА	Standard ED Eval	p-value
Dx Testing during Index Stay* (n, %)			<0.0001
Patients with 0 tests	9 (1.8%)	110 (22.1%)	
Patients with 1 test	376 (75.0%)	336 (67.3%)	
Patients with ≥ 2 tests	116 (23.2%)	54 (10.6%)	
Cumulative Invasive Coronary Angiography <sup>**</sup> (n, %)	60 (12.0%)	40 (8.0%)	0.04
Cumulative Interventions ** (n, %)	32 (6.4%)	21 (4.2%)	0.16
PCI CABG	27 (5.4%) 5 (1.0%)	17 (3.4%) 4 (0.8%)	
Cumulative Radiation Exposure ** (CCTA + SPECT + ICA: mean ± SD per patient in mSv)	14.3 ± 10.9	5.3 ± 9.6	<0.0001

**ROMICAT II** 

\* includes CCTA, SPECT, Echo, ETT, and ICA \*\* includes index hospitalization and 28 day follow-up

#### **Costs of Care**



Costs*	CCTA mean ± SD	Standard ED Eval mean ± SD	% Diff	p-value
ED#	2,053 ± 1,076	2,532 ± 1,346	-19%	<0.0001
Hospital	1950 ± 6,817	1,297 ± 5,316	+50%	0.17
Total	4,004 ± 6,907	3,828 ± 5,289	+5%	0.72

\* cost per patient (dollars) in a subset of 650 patients from 5 centers # includes observation unit

#### Summary



- In ED pts with CP suggestive of ACS an evaluation strategy incorporating CCTA early on
  - Significantly reduces length of stay and time to diagnosis
  - Increases direct ED discharge rates without apparent increase in missed ACS
  - No increase in costs of care despite more diagnostic testing in the CCTA arm when compared to current standard ED evaluation

## Limitations



- Enrollment limited to weekday business hrs, but two week 24/7 screen for pts eligible outside enrollment hrs showed no differences in age, gender, ethnicity, and potential study eligibility
- Lack of statistical power to determine differences in health outcomes

#### **Conclusions**



#### **ROMICAT-II**

First prospective multicenter randomized controlled trial to demonstrate that CCTA incorporated early into an ED evaluation strategy improves clinical decision making for ED triage compared to a standard ED evaluation for pts with CP suggestive of ACS

#### Thank you!



